Thermo Fisher Scientific (TMO) 10-K Summary — Year Ended Dec 31, 2025
Thermo Fisher Scientific filed its annual report, showing a revenue increase from the previous year. Operating cash flow exceeded net income, and the company maintained a strong financial position.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Thermo Fisher Scientific filed its annual report, showing a revenue increase from the previous year. Operating cash flow exceeded net income, and the company maintained a strong financial position.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$44.6B
Revenue reported for the fiscal year.
Operating income
$7.7B
Income from operations reported for the year.
Net income
$6.7B
Net income reported for the year.
Operating cash flow
$7.8B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $44.9B | +14.5% |
| Dec 31, 2023 | $42.9B | -4.6% |
| Dec 31, 2024 | $42.9B | +0.1% |
| Dec 31, 2025 | $44.6B | +3.9% |
Business overview
The supplied filing sections do not provide a description of the company's business operations.
Financial performance
Revenue increased compared to the prior year, while operating income and net income remained substantial. The company generated robust operating cash flow, which was higher than net income.
Material risks
No specific risk factors were provided in the supplied filing sections.
Liquidity and capital
The company reduced net interest expense through interest rate swap arrangements. It also recognized deferred tax benefits from domestication transactions and capital losses, offset partly by pension settlement charges.
What to watch
The impact of the tax legislation enacted during the filing period on future tax rates and net income.